Terminated PHASE4 INTERVENTIONAL 2-arm NCT01079364

Better Acceptance of Single Injection Apidra Added to Once Daily Lantus Versus Twice Daily Premixed Insulin in Real Life Use Setting (BASAAL PLUS)

Better Acceptance of a Single Injection Apidra (Insulin Glulisine) Added to Once Daily Lantus (Insulin Glargine) Versus Twice Daily Premixed Insulin in a Real Life Use Setting

Sponsor: Sanofi

Conditions Diabetes Mellitus, Type 2

Interventions Insulin glargine Insulin glulisine Premixed insulin (Insulin Aspart 30/70 )

Updated 5 times since 2017 Last updated: May 27, 2013 Started: Jan 31, 2010 Primary completion: Jul 31, 2012 Completion: Jul 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Slow recruitment

Other terminated trials from Sanofi

See all terminations from Sanofi

Other Diabetes Mellitus, Type 2 trials with similar outcome

Browse all Diabetes Mellitus, Type 2 trials

This PHASE4 trial investigates Diabetes Mellitus, Type 2 and is currently terminated or withdrawn. Sanofi leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE4
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE4
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE4
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE4
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE4

First recorded

Jan 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sanofi

Data source: Sanofi

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Gouda, Netherlands